

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 June 2024 (27.06.2024)



(10) International Publication Number
WO 2024/133588 A1

(51) International Patent Classification:

A61K 38/08 (2019.01) A61K 47/26 (2006.01)
A61K 9/08 (2006.01) A61K 47/36 (2006.01)
A61K 38/17 (2006.01) A61K 47/42 (2017.01)
A61K 9/00 (2006.01) A61P 35/00 (2006.01)
A61K 47/18 (2017.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2023/087135

(22) International Filing Date:

20 December 2023 (20.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/476,228 20 December 2022 (20.12.2022) US
23153990.9 30 January 2023 (30.01.2023) EP
20230275 14 March 2023 (14.03.2023) NO

(71) Applicant: **LYTIX BIOPHARMA AS** [NO/NO]; Sandak-
erveien 138, 0484 Oslo (NO).

(72) Inventors: **STENSRUD, Gry**; Solveien 9, 1482 Nit-
tedal (NO). **SVEINBJØRNSSON, Baldur**; Nydalsveien
22A, 0484 Oslo (NO). **PÉREZ GONZÁLEZ, Raúl**; avd.
Bruselas 9, 01003 Vitoria-Gasteiz (ES). **GARTZIANDIA
LOPEZ DE GOIKOETXEA, Oihane**; Avenida Urbasa
20, 31809 Olazti (ES).

(74) Agent: **DEHNS**; St Bride's House, 10 Salisbury Square,
London EC4Y 8JD (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS COMPRISING AN ONCOLYTIC PEPTIDE AND CHITOSAN

(57) Abstract: The disclosure herein relates to compositions, kits and their use for treating a subject, e.g. a patient, having a tumor by administering to the subject such compositions.

WO 2024/133588 A1